The future of migraine treatments belongs to CGRP drugs, says professor

One of the scientist who discovered the drug class that has risen in popularity within migraine treatment in recent time predicts a bright future for CGRP drugs.

Jes Olesens, one of the scientist who discovered the drug class of CGRP inhibitors | Photo: Rigshospitalet / PR

The newest generation of migraine treatments, which includes Lundbeck’s Vyepti, will become the first treatment choice when over-the-counter options have no effect, says Jes Olesen, the professor and neurologist who helped discover this new drug class, to Danish media Medicinsk Tidsskrift.

Olesen’s research helped bring on the breakthrough discovery of CGRP antagonists, a drug class that has risen in popularity when treating migraines due to its ability to prevent rather than only treat episodes. The current first choice, the drug family known as triptans, only alleviates migraines after they start.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs